Coronavirus disease 2019 (COVID-19) is a mild to moderate respiratory tract infection, however,
a subset of patients progress to severe disease and respiratory failure. The mechanism …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
has led to the development of various vaccines. Real-life data on immune responses …

COVID ‐19 pandemic caused by SARS ‐CoV‐2 infection is a public health emergency. COVID
‐19 typically exhibits respiratory illness. Unexpectedly, emerging clinical reports indicate …

Background Monoclonal antibodies (mAb) have been introduced as a promising new
therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their …

The face of hepatitis C virus (HCV) therapy is changing dramatically. Direct-acting antiviral
agents (DAAs) specifically targeting HCV proteins have been developed and entered clinical …

Nanoparticles displaying native proteins are attractive for many applications, including
vaccinology. Virus-based nanoparticles are easily tailored by genetic means, commonly by …

Background Fast and reliable detection of SARS-CoV-2 is crucial for efficient control of the
COVID-19 pandemic. Due to the high demand for SARS-CoV-2 testing there is a worldwide …

Background: Differences in interlaboratory research protocols contribute to the conflicting
data in the literature regarding engineered nanomaterial (ENM) bioactivity. Objectives: …

Background Monoclonal antibodies (mAbs) that target severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron variants. …

Abstract Evaluation and power of seroprevalence studies depend on the performed
serological assays. The aim of this study was to assess four commercial serological tests from …